文献速递心力衰竭与心肌病

电子患者激活工具促进射血分数降低心衰患者药物治疗强化:EPIC-HF试验

An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial.
PubMed 文献 · Circulation · 2020-11-17

EPIC-HF试验将306例射血分数降低心衰患者随机分为常规护理组与患者激活工具组(3分钟视频和1页清单,在心脏科门诊前1周、3天和24小时电子推送)。主要终点为门诊前至门诊后30天内指南导向药物治疗(GDMT)的启动或剂量强化比例。结果显示干预组49.0% vs 对照组29.7%(P=0.001)发生GDMT启动或强化,且多数调整发生在门诊就诊时,以剂量上调为主。30天两组死亡、住院或急诊就诊无显著差异。

要点

  • 电子患者激活工具在门诊前推送可提高GDMT启动或强化比例(49.0% vs 29.7%)。
  • 多数GDMT调整发生在门诊就诊时,以剂量上调为主。
  • 30天住院或急诊就诊无显著差异,无死亡事件。

核心结论

  • 在心脏科门诊前电子推送患者激活工具可改善临床医生对GDMT的强化。

研究设计与样本

  • EPIC-HF为随机对照试验,纳入来自多样化医疗系统的射血分数降低心衰患者,随机分为常规护理组与患者激活工具组;工具为3分钟视频和1页清单,在心脏科门诊前1周、3天和24小时电子推送。
  • 共入组306例患者,其中290例在研究期间就诊(干预组145例,对照组145例);中位年龄65岁,女性29%,黑人11%,西班牙裔7%,中位射血分数32%。

主要发现

  • 从心脏科门诊前至门诊后30天,干预组49.0% vs 对照组29.7%发生GDMT启动或强化(P=0.001)。
  • 多数GDMT调整发生在临床医生接诊时,且涉及剂量上调。
  • 30天两组无死亡事件,住院或急诊就诊无显著差异。
  • 门诊前数据显示显著GDMT机会:无患者使用β受体阻滞剂、沙库巴曲缬沙坦和盐皮质激素受体拮抗剂的目标剂量。

临床怎么用

  • 可在心脏科门诊前通过电子方式向射血分数降低心衰患者推送患者激活工具(视频和清单),鼓励患者与临床医生协作做出「一个积极改变」。
  • 该干预可提高门诊就诊时GDMT启动或剂量强化的比例,且未增加30天住院或急诊就诊风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Major gaps exist in the routine initiation and dose up-titration of guideline-directed medical therapies (GDMT) for patients with heart failure with reduced ejection fraction. Without novel approaches to improve prescribing, the cumulative benefits of heart failure with reduced ejection fraction treatment will be largely unrealized. Direct-to-consumer marketing and shared decision making reflect a culture where patients are increasingly involved in treatment choices, creating opportunities for prescribing interventions that engage patients. METHODS: The EPIC-HF (Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction) trial randomized patients with heart failure with reduced ejection fraction from a diverse health system to usual care versus patient activation tools-a 3-minute video and 1-page checklist-delivered electronically 1 week before, 3 days before, and 24 hours before a cardiology clinic visit. The tools encouraged patients to work collaboratively with their clinicians to "make one positive change" in heart failure with reduced ejection fraction prescribing. The primary endpoint was the percentage of patients with GDMT medication initiations and dose intensifications from immediately preceding the cardiology clinic visit to 30 days after, compared with usual care during the same period. RESULTS: EPIC-HF enrolled 306 patients, 290 of whom attended a clinic visit during the study period: 145 were sent the patient activation tools and 145 were controls. The median age of patients was 65 years; 29% were female, 11% were Black, 7% were Hispanic, and the median ejection fraction was 32%. Preclinic data revealed significant GDMT opportunities, with no patients on target doses of β-blocker, sacubitril/valsartan, and mineralocorticoid receptor antagonists. From immediately preceding the cardiology clinic visit to 30 days after, 49.0% in the intervention and 29.7% in the control experienced an initiation or intensification of their GDMT (P=0.001). The majority of these changes were made at the clinician encounter itself and involved dose uptitrations. There were no deaths and no significant differences in hospitalization or emergency department visits at 30 days between groups. CONCLUSIONS: A patient activation tool delivered electronically before a cardiology clinic visit improved clinician intensification of GDMT. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03334188.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Allen LA, Venechuk G, McIlvennan CK, et al. An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial. Circulation. 2020. PMID: 33201741. doi:10.1161/CIRCULATIONAHA.120.051863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。